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Donald	Trump’s	interim	Opioid	Commission	report
did	not	mention	drug	courts.	Here’s	why	that’s	a
positive	step.		
Last	week,	President	Trump	declared	America’s	opioid	crisis	to	be	a	“public	health	emergency”,
announcing	measures	to	tackle	the	problem	including	expanding	access	to	treatment.	John	Collins
writes	that,	in	a	positive	and	perhaps	surprising	move,	in	its	interim	report,	Trump’s	Commission	did
not	mention	drug	courts,	a	politically	popular	approach	to	tackling	substance-abuse.	He	argues	that
drug	courts,	far	from	being	a	key	intervention,	are	frequently	costly,	inefficient	and	merely	solidify	an
inappropriate	reliance	on	the	criminal	justice	system	to	manage	what	has	always	been	a	public
health	issue.
John	Collins	will	be	speaking	at	the	LSE	Event,	“Militarisation	and	the	“War	on	Crime”	at	6:30pm	on
Tuesday,	7	November,	2017.	More	details	and	ticket	information.
No	one	should	underestimate	the	opioid	problem	facing	the	United	States.	As	the	White	House’s	Commission	on
Combating	Drug	Addiction	and	the	Opioid	Crisis	highlighted	in	its	interim	report	to	the	President	in	July,	opioid
overdoses	have	quadrupled	since	1999	“[w]ith	approximately	142	Americans	dying	every	day,	America	is
enduring	a	death	toll	equal	to	Sept.	11	every	three	weeks”.	Following	decades	where	the	opioid	(specifically
heroin)	problem	appeared	to	be	in	decline,	there	has	been	a	sudden	and	radical	resurgence	in	morbidity,
mortality	and	quality	of	life	indicators.
Meanwhile,	public	policies,	still	recovering	from	the	negative	outcomes	of	the	“war	on	drugs”	of	the	1970s,	80s
and	90s,	are	drastically	underdeveloped	and	have	left	the	US	Government	underequipped	to	manage	current
problems.	In	the	midst	of	all	this,	the	public	and	many	elected	officials	are	demanding	strong	action.	Despite	a
recommendation	of	his	own	commission	in	July	to	declare	a	national	emergency	to	begin	to	tackle	the	crisis,	the
Trump	administration	did	precisely	nothing	for	a	further	three	months,	initially	resorting	to	hollow	platitudes	about
border	enforcement	and	the	role	of	the	US’	neighbours	in	enabling	the	trade,	without	in	any	way	acknowledging
the	home-grown	nature	of	the	current	use	epidemic.
Now	that	President	Trump	has	declared	a	public	health	emergency,	critics	are	quick	to	point	out	that	it	doesn’t	go
far	enough	and	is	currently	unfunded.	Although	Congress	bears	significant	responsibility	for	its	own	aversion	to
expanding	public	health	services	and	the	other	mechanisms	highlighted	by	the	President’s	Opioid	Commission,
key	questions	can	at	least	be	asked	about	where	emergency	resources	should	be	directed.	The	President’s
Commission	provides	some	useful	points	of	direction.	in	particular,	lessening	the	enormous	gap	between
treatment	coverage	and	need.	As	the	Commission	highlights:
only	10	percent	of	the	nearly	21	million	citizens	with	a	substance	use	disorder	(SUD)	receive	any	type
of	specialty	treatment	according	to	the	most	recent	National	Survey	on	Drug	Use	and	Health.
Nevertheless,	civil	rights	advocates	are	right	to	point	out	a	fundamental	difference	between	policy	responses	to
this	epidemic	and	to	previous	ones	–	that	the	median	user	is	increasingly	perceived	as	white	and	middle	class.
This,	they	correctly	highlight,	is	manifest	in	a	quick	recourse	to	public	health	narratives	grounded	in	a	greater
respect	for	the	individual.	Poorer,	minority,	inner	city	communities,	so	often	ground	zero	of	the	crack	epidemic	of
the	1980s,	were	targeted	for	aggressive	policing	and	incarceration	practices.	These	did	little	to	quell	the	problems
associated	with	drugs	but	greatly	exacerbated	the	generational	impacts	of	the	drug	markets	through	mass
incarceration	and	the	spread	of	HIV/AIDS	as	public	health	policies	were	shunned.
Regardless,	the	policies	outlined	in	President’s	Commission	(even	if	the	President	himself	is	slow	to	heed	them)
include	useful	steps	forward.	In	particular:
1.	 Expanding	access	to	treatment	coverage	by,	for	example,	granting	“waiver	approvals	for	all	50	states	to
quickly	eliminate	barriers	to	treatment	resulting	from	the	federal	Institutes	for	Mental	Diseases	DRAFT	3
USApp – American Politics and Policy Blog: Donald Trump’s interim Opioid Commission report did not mention drug courts. Here’s why that’s a positive
step.  
Page 1 of 4
	
	
Date originally posted: 2017-10-31
Permalink: http://blogs.lse.ac.uk/usappblog/2017/10/31/donald-trumps-opioid-commission-did-not-mention-drug-courts-heres-why-thats-a-positive-step/
Blog homepage: http://blogs.lse.ac.uk/usappblog/
(IMD)	exclusion	within	the	Medicaid	program.	This	will	immediately	open	treatment	to	thousands	of
Americans	in	existing	facilities	in	all	50	states.”
2.	 Mandating	prescriber	training	as	a	form	of	prevention.
3.	 Drastically	expanding	access	to	Medication	Assisted	Treatment	(MAT)	such	as	Methadone,	Buprenorphine
and	others	based	on	a	criteria	of	“what	is	best	for	the	patient”	rather	than	the	mistaken	“prevalent	belief	that
use	of	MAT	does	not	constitute	true	recovery	or	sobriety.”
4.	 Rapidly	expanding	access	to	the	overdose	reversal	drug,	Naloxone	and	equipping	“all	law	enforcement	in
the	United	States	with	naloxone	to	save	lives.”
Others	are	included,	but	in	the	context	of	such	a	wide	treatment	gap	and	a	lack	of	political	understanding	about
key	treatment	modalities	such	MAT	and	a	powerful	overdose	reversal	medicine,	these	points	particularly	stick	out.
Drug	courts	are	still	not	the	answer
What	was	also	positive	and	surprising	was	the	lack	of	mention	of	more	problematic	interventions	which,	despite
very	questionable	return	on	investment,	remain	politically	popular.	In	particular,	Drug	Courts,	or	Drug	Treatment
Courts.	A	number	of	recent	press	responses	have	highlighted	these	as	a	key	intervention	in	the	opioid	crisis	and
painted	the	evidence	as	stellar	and	clear.	As	Fred	R	Conrad	recently	argued	in	the	Guardian,	they	give	families	“a
second	chance”.	Further,	the	US	government	has	long	been	actively	exporting	them	to	other	countries	as	a	model
intervention,	regardless	of	local	needs.		In	the	US,	drug	courts	can	be	described	as:
specialized	court	dockets,	or	portions	of	judges’	calendars	of	cases,	that	generally	target	nonviolent
offenders	with	substance-abuse	problems.	These	programs	provide	offenders	with	intensive	court
supervision,	mandatory	drug	testing,	substance-abuse	treatment,	and	other	social	services	as	an
alternative	to	adjudication	or	incarceration…to	break	the	cycle	of	substance	abuse,	addiction,	and
crime	by	changing	the	behavior	of	substance-abusing	offenders.
Drug	courts	remain	a	simultaneously	popular,	controversial,	expensive	and	problematic	intervention.	Further,	the
evidence	used	to	support	them	is	too	often	incomplete,	misrepresented	or	else	based	on	anecdote.	As	a	recent
advocacy	article	by	Newt	Gingrich	and	Van	Jones	argued,	“[t]here	are	over	3,000	treatment	courts	in	the	United
States,	according	to	The	National	Association	of	Drug	Court	Professionals,	and	they	help	about	150,000	people
go	into	addiction	treatment	each	year.”
Their	statement	points	to	a	number	of	key	criticisms	of	drug	courts	as	a	model.	Firstly,	for	treatment	to
be	ethical	and	effective	it	should	be	voluntary	rather	than	coerced.	The	goal	is	to	provide	a	range	of	social	and
treatment	services	which	enable	individuals	with	substance	use	disorders	to	get	help	before	they	are	forced	into
legal	trouble.	The	idea	of	courts	“helping”	people	into	treatment	is	fundamentally	at	odds	with	increasingly
prevalent	norms	of	human	rights	and	public	health-based	approaches	to	treatment.	Further,	it	is,	at	an	aggregate
level,	simply	inefficient.	The	expense	of	administering	an	individual’s	treatment	regimen	via	a	costly	labour
intensive	legal	process	comes	at	the	large	opportunity	cost	of	investing	in	genuinely	accessible	and	voluntary
community-based	treatment	services.	Simultaneously,	by	UN	estimates,	90	percent	of	people	who	use	drugs	do
not	do	so	problematically	and	thereby	do	not	require	treatment.	Drug	courts	have	been	criticised	for	pushing
individuals	into	scarce	treatment	services	for	which	they	have	no	medical	need.	In	so	doing	Drug	Courts	can
reduce	the	availability	of	treatment	services	of	those	seeking	them.
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“Courtroom	One	Gavel”	by	Joe	Gratz	is	licensed	under	CC0	Public	Domain.
A	number	of	studies	have	highlighted,	there	is	a	“general	propensity	for	drug	courts	to	target	lower-risk	offenders
who	would	otherwise	end	up	on	probation”.	The	outcome	is	driven	by	a	desire	to	show	positive	results	and
thereby	select	the	most	likely	applicants	to	complete	the	drug	court,	even	if	in	many	cases	they	don’t	meet	basic
clinical	criteria	of	being	drug-dependent.	Further,	given	their	stated	aim	of	reducing	incarceration	a	2013	meta-
analysis	found	that	while	they	may	have	an	impact	on	recidivism	of	roughly	10	percent	in	certain	groups	(a	figure
which	other	scholars	dispute	based	on	the	quality	of	data	available),	but	minimal	impacts	on	others,	“Drug	courts
do	not	reduce	the	aggregate	amount	of	time	that	offenders	spend	behind	bars.”
Ideology,	not	medically,	based	treatments
A	broader	concern	as	it	relates	to	best	practice	opioid	treatment	rests	with	the	refusal	of	many	drug	courts	to
allow	Medication	Assisted	Treatment	(MAT)	due	to	an	ideological	predisposition	towards	abstinence.	As	a	2013
survey	of	US	drug	courts	highlighted,	virtually	all	had	opioid-dependent	participants,	but	only	25	percent	permitted
methadone	while	only	40	percent	permitted	buprenorphine	maintenance.		Although	the	Federal	government	has
made	strides	since	2015	to	force	drug	courts	to	increase	MAT	provision	or	risk	losing	federal	funding,	it	is	not	yet
clear	whether	this	will	have	sufficient	impact.	Meanwhile,	this	tendency	towards	ideology-based	treatment
decisions	has	been	criticised	by	public	health	experts	as	enabling	a	situation	whereby	Judges	frequently	end	up
making	medical	decisions,	for	which	they	have	insufficient	or	no	expertise,	qualifications	or	training	to	make.
In	the	context	of	a	public	health	emergency	states	should	be	wary	about	embarking	on	costly	programmes	which
have	questionable	cost-benefit	calculations	and	provide	genuine	opportunity	costs	in	terms	of	investment	in
community-based	treatment	options.	Drug	courts	remain	a	popular	idea	but	a	problematic	intervention.	As	with
any	public	policy	intervention	promising	miraculous	results	but	underpinned	by	questionable	evidence,	one	must
approach	their	adoption	with	caution.	Perhaps	one	way	to	think	of	drug	courts,	in	the	US	in	particular,	is	as	a	less
sub-optimal	outcome	than	more	“classical”	“war	on	drugs”	approaches.	In	places	with	deeply	embedded
criminalisation	of	drug	involvement,	drug	courts	may	prove	an	available	framework	to	attempt	diversion	from	the
cycle	of	incarceration.	However,	with	the	increasingly	wide	recognition	that	drug	dependence	issues	are	best
dealt	with	outside	a	criminal	justice	orientation	they	may	increasingly	be	viewed	as	an	anachronism	and	not	one
for	scale	up	under	the	current	crisis.
Please	read	our	comments	policy	before	commenting.												
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Note:		This	article	gives	the	views	of	the	author,	and	not	the	position	of	USAPP–	American	Politics	and	Policy,	nor
of	the	London	School	of	Economics.
Shortened	URL	for	this	post:	http://bit.ly/2ygfud3
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